Risk of Second Primary Malignancies After CAR-T Therapy - EMJ

Risk of Second Primary Malignancies After CAR-T Therapy

1 Mins
Hematology

A new study has raised awareness about the risk of second primary malignancies (SPM) in patients treated with chimeric antigen receptor (CAR) T-cell therapy for hematologic cancers like lymphoma and myeloma. CAR-T therapy, a powerful immunotherapy, is known for its effectiveness, but this research highlights potential long-term adverse effects. 

Researchers from the Memorial Sloan Kettering Cancer Research Institute, conducted a systematic review and meta-analysis of 18 clinical trials and 7 real-world studies, involving 5,517 patients. They identified 326 cases of SPMs, with an overall estimated risk of 6.0% ((95% confidence interval, 4.8%–7.4%) over a median follow-up period of 21.7 months. Hematologic malignancies were the most common SPMs (37%), followed by solid tumours (27%) and non-melanoma skin cancers (16%). 

The study revealed that SPM risks were influenced by factors such as treatment setting, follow-up duration, and the number of prior treatments. Interestingly, a comparison of CAR-T with standard-of-care treatments showed no significant difference in SPM risk between the two (P = 0.92). 

While SPMs are a clinically relevant concern, the study emphasizes that CAR-T therapy does not seem to carry a higher risk of SPMs compared to previous treatments. The findings underscore the importance of long-term monitoring for patients undergoing CAR-T therapy to manage potential secondary cancers. 

Helena Bradbury, EMJ 

 

Reference 

Tix T et al. Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clinical Cancer Research. 2024  

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given